 |
0 Diseases |  |
0 Trials |
|
0 Trials |  |
15 News |  |
- | SSP-002358 / Takeda
Phase classification: Selective 5-HT4 Receptor Agonist and Proton Pump Inhibitor (PPI) in Subjects With Gastroesophageal Reflux Disease (GERD) (clinicaltrials.gov) - Jun 9, 2021
P2b, N=480, Completed, Sponsor: Shire
Phase classification: P2 --> P2b
- || SHP557 / Takeda
Clinical, Journal: Predicting lethal pulmonary hypoplasia in congenital diaphragmatic hernia (CDH): Institutional experience combined with CDH registry outcomes. (Pubmed Central) - May 27, 2021
However, our data suggest resource utilization is significant when unable to reach pCO2 ≤100 despite resuscitation. Morbidity remains high in this group.
- | SHP557 / Takeda
Journal: Screening for Resistance to PVY in Australian Potato Germplasm. (Pubmed Central) - Mar 27, 2021
The RYSC3, M45, and STM0003 markers were therefore able to identify all the 13 cultivars that were resistant to both strains of PVY. Therefore, these markers will enable the identification of genotypes with resistance to PVY, and enable PVY resistant parents to be used for the development of superior progeny; these genetic markers can be used for MAS in the Australian potato breeding program.
- | SHP557 / Takeda
Journal: Complete mitochondrial genome of Micractinium singularis MM0003 (Chlorellaceae, Trebouxiophyceae). (Pubmed Central) - Dec 29, 2020
This mitogenome has 75,931 bp in length and consists of 62 genes including 32 protein-coding, 3 rRNA, and 27 tRNA genes. The overall GC content of the genome is 27.5%.
- | SHP557 / Takeda
Journal: Complete chloroplast genome of Micractinium singularis MM0003 (Chlorellaceae, Trebouxiophyceae). (Pubmed Central) - Dec 29, 2020
This plastome has 139,597 bp in length and consists of 106 genes including 77 protein-coding, 3 rRNA, and 26 tRNA genes. The overall GC content of the genome is 34.0%.
- | SHP557 / Takeda
Journal: Genome-Wide Identification and Expression Analyses of the Chitinases under Cold and Osmotic stress in Ammopiptanthus nanus. (Pubmed Central) - Jun 27, 2019
These chitinases might play key roles in the tolerance to these abiotic stress in A. nanus and have potential for biotechnological applications. This study provided important data for understanding the biological functions of chitinases in A. nanus.
- |||| SSP-002358 / Takeda
Trial completion: Selective 5-HT4 Receptor Agonist and Proton Pump Inhibitor (PPI) in Subjects With Gastroesophageal Reflux Disease (GERD) (clinicaltrials.gov) - Jun 4, 2013
P2, N=480, Completed, Sponsor: Shire-Movetis NV
This study provided important data for understanding the biological functions of chitinases in A. nanus. Active, not recruiting --> Completed
- | SSP-002358 / Takeda
Trial termination: An Explorative Trial to Evaluate the Pharmacodynamic Effect of SPD557 on Reflux Parameters in Refractory GERD Patients (clinicaltrials.gov) - Apr 21, 2013
P2, N=67, Terminated, Sponsor: Movetis
Completed --> Terminated; This study was terminated early due to recruitment difficulties. There were no safety concerns.
- SSP-002358 / Takeda
Trial completion: Adsorption, Metabolism and Excretion (AME) of Single Dose Radiolabeled SPD557 in Volunteers (clinicaltrials.gov) - Apr 18, 2013
P1, N=6, Completed, Sponsor: Shire-Movetis NV
There were no safety concerns. Recruiting --> Completed
- SSP-002358 / Takeda
New P1 trial: Adsorption, Metabolism and Excretion (AME) of Single Dose Radiolabeled SPD557 in Volunteers (clinicaltrials.gov) - Feb 6, 2013
P1, N=6, Completed, Sponsor: Shire-Movetis NV
- SSP-002358 / Takeda
Enrollment change: An Explorative Trial to Evaluate the Pharmacodynamic Effect of SPD557 on Reflux Parameters in Refractory GERD Patients (clinicaltrials.gov) - Jul 22, 2012
P2, N=67, Terminated, Sponsor: Movetis
Recruiting --> Completed N=90 --> 67
- ||||| SSP-002358 / Takeda
New P2 trial: Selective 5-HT4 Receptor Agonist and Proton Pump Inhibitor (PPI) in Subjects With Gastroesophageal Reflux Disease (GERD) (clinicaltrials.gov) - Nov 15, 2011
P2, N=480, Completed, Sponsor: Shire-Movetis NV
- | SSP-002358 / Takeda
Trial completion: SSP-002358 Drug Interaction Study With Omeprazole (clinicaltrials.gov) - Sep 28, 2011
P1, N=42, Completed, Sponsor: Shire-Movetis NV
N=90 --> 67 Enrolling by invitation --> Completed
- | SSP-002358 / Takeda
New P1 trial: SSP-002358 Drug Interaction Study With Omeprazole (clinicaltrials.gov) - Aug 9, 2011
P1, N=42, Completed, Sponsor: Shire-Movetis NV